This study investigates maternal serum Stathmin-1 (STMN-1) levels in pregnancies complicated by preeclampsia and severe preeclampsia, compared to healthy pregnancies. The aim is to explore potential differences in STMN-1 levels among these groups to better understand its role in preeclampsia pathophysiology. Maternal serum STMN-1 levels will be measured between 32-34 weeks of gestation, and patients will be monitored until delivery to assess whether they develop preeclampsia or severe preeclampsia.
Study Type
OBSERVATIONAL
Enrollment
84
Cam and Sakura City Hospital
Istanbul, Turkey (Türkiye)
Maternal Serum Stathmin-1
To compare Stathmin-1 Levels between the pre-eclampsia and the control group.
Time frame: Up to 8 weeks (Patients will be followed from inclusion in the study until the end of their pregnancy.)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.